Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HX009 in Advanced Solid Tumors
NCT05731752Phase 1Active, not recruiting
- Sponsor
- Hanx Biopharmaceuticals
- Start
- May 2020
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HX009 in solid tumor and melanoma, sponsored by Hanx Biopharmaceuticals. Primary endpoints: Incidence of Dose Limiting Toxicities and Incidence of adverse events. Started May 2020; status: active, not recruiting.
02
Drugs
HX009
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT05731752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05731752.